National Consensus Meeting to Decide Outcome Measures for Adults with SMA

National Consensus Meeting to Decide Outcome Measures for Adults with SMA

On September 9th and 10th in Ottawa, Ontario, 14 adult SMA experts including, clinicians, allied health care providers, patient organization representatives, and the Canadian Neuromuscular Disease Registry (CNDR) representatives gathered to reach an updated national consensus on outcome measures for adults with SMA. With increasing experience following adults on novel disease-modifying therapy alongside advances in standardized outcome measures, it was essential to revisit the prior Canadian adult SMA toolkit (2020), with a renewed emphasis on meaningful outcomes for patients. The consensus work will help to support discussions within individual provinces to understand response to therapy, advocate for appropriate access to high-cost therapeutics, and enable national comparisons. 

 

During this multi-day meeting, the group considered a broad spectrum of outcome measures that may be applicable to adult SMA to determine a core set of recommended, suggested, and exploratory measures, based on the individual’s current functional status. To support measure selection, patient preferences and perspectives, practitioner experiences, feasibility (including time and equipment needed), and provincial payer requirements were discussed.  

 

The meeting concluded with a vote to determine which outcome measures should be completed across Canada for adults with SMA, and consensus was reached. Based on the new consensus results, the CNDR will update its SMA dataset accordingly.  Official results from this national consensus-building meeting will be released soon.  

National Consensus Meeting to Decide Outcome Measures for Adults with SMA

Read next...

CPNG 2026

Zolgensma® Safety Update and CPNG Guidance for Families

The Canadian Pediatric Neuromuscular Group (CPNG) has issued a statement for families regarding recent reports of tumours in children treated with Zolgensma® (onasemnogene abeparvovec) gene therapy for spinal muscular atrophy (SMA). The statement outlines current evidence, considerations for follow-up care, and information for families and healthcare providers.

2026 Trainee Publication of the Year Awardee Spotlight on Jules Granet

Could You Be Our Next Awardee? Meet Jules Granet, NMD4C’s 2026 Publication of the Year Awardee

Nominations are open till by 18 January 2027!
In 2026, Jules Granet, a PhD Candidate at McGill University and trainee in Dr. Natasha Chang’s laboratory received an NMD4C Publication of the Year Award for research investigating how muscle stem cell dysfunction contributes to impaired muscle regeneration in Duchenne muscular dystrophy. Nominate yourself or a neuromuscular colleague whose research, clinical care, leadership, advocacy, or community contributions deserve to be recognized.

Save the date: 8th Ottawa International Conference On Neuromuscular Disease & Biology

Early Bird Registration Now Open: 8th Ottawa International Conference On Neuromuscular Disease & Biology

We are happy to announce that early bird registration is now open for the 8th Ottawa International Conference On Neuromuscular Disease & Biology which will be held on October 14-16, 2027 at the Fairmont Château Laurier in Ottawa, Canada. Now under the leadership of NMD4C Investigators; Dr. Mireille Khacho, Dr. Hanns Lochmuller, Dr. Bernard Jasmin, and Dr. Rashmi Kothary.